全文获取类型
收费全文 | 2259篇 |
免费 | 130篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 89篇 |
儿科学 | 39篇 |
妇产科学 | 51篇 |
基础医学 | 330篇 |
口腔科学 | 39篇 |
临床医学 | 174篇 |
内科学 | 301篇 |
皮肤病学 | 145篇 |
神经病学 | 243篇 |
特种医学 | 148篇 |
外科学 | 296篇 |
综合类 | 24篇 |
预防医学 | 81篇 |
眼科学 | 72篇 |
药学 | 139篇 |
中国医学 | 12篇 |
肿瘤学 | 238篇 |
出版年
2023年 | 15篇 |
2022年 | 45篇 |
2021年 | 45篇 |
2020年 | 24篇 |
2019年 | 60篇 |
2018年 | 46篇 |
2017年 | 61篇 |
2016年 | 65篇 |
2015年 | 122篇 |
2014年 | 112篇 |
2013年 | 137篇 |
2012年 | 158篇 |
2011年 | 169篇 |
2010年 | 99篇 |
2009年 | 113篇 |
2008年 | 148篇 |
2007年 | 131篇 |
2006年 | 122篇 |
2005年 | 102篇 |
2004年 | 86篇 |
2003年 | 61篇 |
2002年 | 46篇 |
2001年 | 47篇 |
2000年 | 51篇 |
1999年 | 35篇 |
1998年 | 19篇 |
1997年 | 21篇 |
1996年 | 26篇 |
1995年 | 10篇 |
1994年 | 24篇 |
1993年 | 17篇 |
1992年 | 15篇 |
1991年 | 16篇 |
1990年 | 16篇 |
1989年 | 24篇 |
1988年 | 12篇 |
1987年 | 15篇 |
1986年 | 17篇 |
1985年 | 11篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 7篇 |
1981年 | 11篇 |
1980年 | 8篇 |
1979年 | 4篇 |
1977年 | 6篇 |
1975年 | 6篇 |
1974年 | 6篇 |
1973年 | 8篇 |
1972年 | 2篇 |
排序方式: 共有2421条查询结果,搜索用时 15 毫秒
41.
Yoo Sang Baek Se Ha Park Jinok Baek Joo Young Roh Hee Joo Kim 《The Journal of dermatology》2020,47(2):163-165
Although lupus erythematosus is known to be more common among women of color, the study populations in previous reports were predominantly Caucasian and there is scarce information on Asian patients. Therefore, we performed a retrospective study using a nationwide population-based cohort in South Korea. The average annual incidence of cutaneous lupus was 4.36/100 000. Among 634 patients with cutaneous lupus, 20.8% had systemic disease: cutaneous lupus was diagnosed before systemic lupus in 4.26% and after systemic lupus in 8.52%. More female patients than male patients developed systemic lupus erythematosus. The average time to progression to systemic lupus was 1.53 ± 1.46 years. 相似文献
42.
Annals of Surgical Oncology - 相似文献
43.
The challenges posed by acute brain injury (ABI) involve the management of the initial insult in addition to downstream inflammation, edema, and ischemia that can result in secondary brain injury (SBI). SBI is often subclinical, but can be detected through physiologic changes. These changes serve as a surrogate for tissue injury/cell death and are captured by parameters measured by various monitors that measure intracranial pressure (ICP), cerebral blood flow (CBF), brain tissue oxygenation (PbtO2), cerebral metabolism, and electrocortical activity. In the ideal setting, multimodality monitoring (MMM) integrates these neurological monitoring parameters with traditional hemodynamic monitoring and the physical exam, presenting the information needed to clinicians who can intervene before irreversible damage occurs. There are now consensus guidelines on the utilization of MMM, and there continue to be new advances and questions regarding its use. In this review, we examine these recommendations, recent evidence for MMM, and future directions for MMM. 相似文献
44.
45.
46.
Myositis ossificans (MO) is a benign condition of non-neoplastic heterotopic bone formation in the muscle or soft tissue. Trauma plays a role in the development of MO, thus, non-traumatic MO is very rare. Although MO may occur anywhere in the body, it is rarely seen in the lumbosacral paravertebral muscle (PVM). Herein, we report a case of non-traumatic MO in the lumbosacral PVM. A 42-year-old man with no history of trauma was referred to our hospital for pain in the low back, left buttock, and left thigh. On physical examination, a slightly tender, hard, and fixed mass was palpated in the left lumbosacral PVM. Computed tomography showed a calcified mass within the left lumbosacral PVM. Magnetic resonance imaging (MRI) showed heterogeneous high signal intensity in T1- and T2-weighted image, and no enhancement of the mass was found in the postcontrast T1-weighted MRI. The lack of typical imaging features required an open biopsy, and MO was confirmed. MO should be considered in the differential diagnosis when the imaging findings show a mass involving PVM. When it is difficult to distinguish MO from soft tissue or bone malignancy by radiology, it is necessary to perform a biopsy to confirm the diagnosis. 相似文献
47.
Young Hak Roh MD Ki Woong Kim MD Nam-Jong Paik MD Tae Kyun Kim MD Hyun Sik Gong MD 《Clinical orthopaedics and related research》2012,470(11):3246-3252
Background
Musculoskeletal complaints influence general health status, but the relative contribution of concurrent upper and lower extremity disabilities on patient perceptions of general health is unclear. 相似文献48.
49.
H.S. Ra S.J. Shin J.H. Kim H. Lim B.C. Cho M.R. Roh 《Journal of the European Academy of Dermatology and Venereology》2013,27(1):e53-e59
Background One of the most common side effects of anti‐cancer therapies is treatment‐induced skin changes, referred to as dermatological toxicities. These dermatological toxicities are noteworthy since they have a negative association with quality of life (QoL). Objectives To evaluate the impact of dermatological toxicities on QoL of cancer patients and to identify the relationship between disease‐related characteristics and QoL and changes in skin protective behaviours following anti‐cancer therapy. Methods Cancer patients (n = 80: stage II–IV) in a longitudinal prospective study completed a battery of questionnaires at the time of enrolment and after 3 months of anti‐cancer therapy. QoL, skin toxicities, smoking and drinking behaviour, sun‐protective and skin care behaviour assessments were performed before and at 3 months after anti‐cancer therapy. QoL was measured with the Dermatology Life Quality Index (DLQI). Results A total of 73 patients completed the study. Among them, 48 patients (65.8%) experienced at least grade 1 skin toxicity at 3 months after anti‐cancer therapy. Hair loss, hyperpigmentation and dry skin were the most common dermatological toxicities. The mean baseline DLQI score changed from 1.38 to 3.49 at 3 months after anti‐cancer therapy. Domain 1 (symptoms and feelings, 1.38 points) was the most greatly impacted among patients by anti‐cancer treatment. Patients who experienced at least grade 1 skin toxicity (P = 0.001, 95% CI: 1.939–4.899), employed (P = 0.042, 95% CI: 0.030–1.476), more highly educated (P = 0.030, 95% CI: 0.161–3.132), and diagnosed with gastric cancer (P = 0.001, 95% CI: 2.141–8.250) or renal cell cancer (P = 0.002, 95% CI: 2.731–11.364) showed significantly higher DLQI scores. Patients showed significant change in skin protective behaviour such as use of body moisturizer (P = 0.021) and change in drinking behaviour (P = 0.006) at 3 months following anti‐cancer therapy. Conclusion Dermatological toxicities due to anti‐cancer therapy affect the QoL of cancer patients. Therefore, health care professionals should pay attention to the psychological effects of skin problems and educate cancer patients to adapt proactive skin protective behaviours to minimize dermatological toxicities of anti‐cancer therapy and maximize QoL. 相似文献
50.
HR Seneviratne D Lankeshwara S Wijeratne N Somasunderam D Athukorale 《BJOG : an international journal of obstetrics and gynaecology》2009,116(13):1722-1728
Objective To evaluate serum insulin levels and insulin sensitivity in women with polycystic ovary syndrome (PCOS) in relation to their glycaemic status.
Design An observational study.
Setting A tertiary-level reproductive health centre in Sri Lanka.
Sample Infertile women diagnosed as having PCOS ( n = 168) on the basis of the Rotterdam criteria were included in the study.
Methods Glycaemic status and serum insulin values were assessed at fasting and at 2 hours after a 75-g oral glucose load and stratified as diabetes mellitus (DM) (10.12%), impaired glucose tolerance (IGT) (23.21%) and normoglycaemia (66.67%). The normoglycaemic group was restratified as groups A (10.7%), B (79.5%) and C (9.8%) on the basis of serum insulin levels, with group A having the lowest and group C the highest values. The Quantitative Insulin Sensitivity Check Index (QUICKI) scores of women with DM and IGT and those in groups A, B and C in the normoglycaemic category were compared.
Main outcome measures Insulin sensitivity in these groups of women.
Results Body mass index (BMI) exceeded 23 kg/m2 in 77.38% of the women. In normoglycaemic women with PCOS, insulin sensitivity was highest in group A. In groups B and C, insulin sensitivities corresponded to those found for women with IGT and DM respectively. This pattern was also reflected in the BMI.
Conclusions Normoglycaemic women with PCOS are heterogeneous regarding insulin sensitivity. The treatment offered to those with DM and IGT could be extended to subgroups B and C of normoglycaemic subjects. Normoglycaemic women with PCOS with high insulin sensitivity (group A) would not qualify for this treatment. 相似文献
Design An observational study.
Setting A tertiary-level reproductive health centre in Sri Lanka.
Sample Infertile women diagnosed as having PCOS ( n = 168) on the basis of the Rotterdam criteria were included in the study.
Methods Glycaemic status and serum insulin values were assessed at fasting and at 2 hours after a 75-g oral glucose load and stratified as diabetes mellitus (DM) (10.12%), impaired glucose tolerance (IGT) (23.21%) and normoglycaemia (66.67%). The normoglycaemic group was restratified as groups A (10.7%), B (79.5%) and C (9.8%) on the basis of serum insulin levels, with group A having the lowest and group C the highest values. The Quantitative Insulin Sensitivity Check Index (QUICKI) scores of women with DM and IGT and those in groups A, B and C in the normoglycaemic category were compared.
Main outcome measures Insulin sensitivity in these groups of women.
Results Body mass index (BMI) exceeded 23 kg/m
Conclusions Normoglycaemic women with PCOS are heterogeneous regarding insulin sensitivity. The treatment offered to those with DM and IGT could be extended to subgroups B and C of normoglycaemic subjects. Normoglycaemic women with PCOS with high insulin sensitivity (group A) would not qualify for this treatment. 相似文献